NCT02678689
CLN2, Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2, Jansky-Bielschowsky Disease, Batten Disease, CLN2 Disease, CLN2 Disorder
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
This Phase 2 open-label, multicenter study will evaluate the safety, tolerability, and efficacy of BMN 190 intracerebroventricular (ICV) administration every other week (qow) for a period of 144 weeks, in patients with CLN2. The study is designed to assess disease progression in CLN2 patients treated with BMN 190 compared to natural history data from untreated historical controls.
All
0 Years to 17 Years
No
BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1), Intraventricular access device
Phase 2
Interventional
14
2016-02
2023-03-13
Columbus, Ohio, United States
Hamburg, , Germany
Rome, Piazza, Italy
London, , United Kingdom
Exclusion Criteria:
By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.
*required fields
"*" indicates required fields